2026년 2월 10일 · Unknown · financial · 출처 Yahoo Finance
As global markets grapple with volatility, driven by concerns over artificial intelligence and geopolitical tensions, investors are increasingly turning their attention to value-oriented segments that may offer more stability. In this context, identifying undervalued stocks in the Asian markets can present unique opportunities for those seeking to capitalize on potential discrepancies between a stock's market price and its estimated intrinsic value.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
Name Current Price Fair Value (Est) Discount (Est) TLB (KOSDAQ:A356860) ₩60000.00 ₩118404.93 49.3% Sino Medical Sciences Technology (SHSE:688108) CN¥22.82 CN¥44.84 49.1% Ningxia Building Materials GroupLtd (SHSE:600449) CN¥13.41 CN¥26.70 49.8% Hyundai Rotem (KOSE:A064350) ₩212500.00 ₩424059.73 49.9% Fuji Media Holdings (TSE:4676) ¥3628.00 ¥7106.09 48.9% EMRO (KOSDAQ:A058970) ₩40850.00 ₩80317.40 49.1% CURVES HOLDINGS (TSE:7085) ¥763.00 ¥1517.50 49.7% CSPC Innovation Pharmaceutical (SZSE:300765) CN¥34.95 CN¥69.46 49.7% Comvita (NZSE:CVT) NZ$0.69 NZ$1.38 50% BEAUTY GARAGE (TSE:3180) ¥1416.00 ¥2830.45 50%
Click here to see the full list of 237 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.
We'll examine a selection from our screener results.
Innovent Biologics
Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products across China, the United States, and internationally, with a market cap of HK$148.18 billion.
Operations: The company generates revenue from its biotechnology segment, which amounts to CN¥11.42 billion.
Estimated Discount To Fair Value: 43.8%
Innovent Biologics is trading at HK$85.4, significantly below its estimated future cash flow value of HK$151.85, highlighting potential undervaluation based on cash flows. The company recently announced a strategic collaboration with Eli Lilly, securing a US$350 million upfront payment and potential milestone payments up to US$8.5 billion, enhancing its financial position. Innovent's robust revenue growth and high earnings forecast further support its attractiveness as an undervalued investment opportunity in Asia.
According our earnings growth report, there's an indication that Innovent Biologics might be ready to expand. Delve into the full analysis health report here for a deeper understanding of Innovent Biologics.SEHK:1801 Discounted Cash Flow as at Feb 2026
Zhaojin Mining Industry
Overview: Zhaojin Mining Industry Company Limited is an investment holding company involved in the exploration, mining, processing, smelting, and sale of gold and other metallic products both in China and internationally, with a market cap of approximately HK$122.64 billion.
Story Continues
Operations: The company generates revenue through the exploration, mining, processing, smelting, and sale of gold and other metallic products in China and international markets.
Estimated Discount To Fair Value: 46.1%
Zhaojin Mining Industry is trading at HK$34.62, substantially below its estimated future cash flow value of HK$64.2, indicating it may be undervalued based on cash flows. The company's earnings grew by 133% over the past year and are forecast to grow significantly at 39.3% annually, surpassing the Hong Kong market average. Despite a low projected return on equity of 19%, Zhaojin's strong earnings trajectory underscores its potential as an undervalued investment in Asia.
Insights from our recent growth report point to a promising forecast for Zhaojin Mining Industry's business outlook. Dive into the specifics of Zhaojin Mining Industry here with our thorough financial health report.SEHK:1818 Discounted Cash Flow as at Feb 2026
Auras Technology
Overview: Auras Technology Co., Ltd. is involved in the manufacturing, processing, and retailing of electronic materials and computer cooling modules across China, Taiwan, Ireland, Singapore, the United States, and internationally with a market cap of NT$100.83 billion.
Operations: The company's revenue is primarily derived from its Electronic Components & Parts segment, which generated NT$19.80 billion.
Estimated Discount To Fair Value: 41.6%
Auras Technology, trading at NT$1105, is significantly below its estimated future cash flow value of NT$1890.74, highlighting potential undervaluation. The company's earnings grew by 27.9% last year and are expected to rise at an impressive 48.75% annually over the next three years, outpacing the Taiwan market average. Despite high non-cash earnings levels, Auras's robust forecasted revenue growth of 34.1% per year strengthens its position as a promising investment in Asia.
Upon reviewing our latest growth report, Auras Technology's projected financial performance appears quite optimistic. Click here to discover the nuances of Auras Technology with our detailed financial health report.TPEX:3324 Discounted Cash Flow as at Feb 2026
Seize The Opportunity
Click here to access our complete index of 237 Undervalued Asian Stocks Based On Cash Flows. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Interested In Other Possibilities?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommend…